Zydus Wellness News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Zydus Wellness from all sources in a single place.

10 Dec 2025

426.40

0.39%

Zydus Lifesciences introduces biosimilar for cancer patients' bone health

Business Standard

Zydus Lifesciences on Wednesday said it has launched a biosimilar for the treatment of osteoporosis and the prevention of skeletal complications in cancer patients. The company has launched Zyrifa, a Denosumab biosimilar. Denosumab is a monoclonal antibody with several indications related to bone health, primarily in the treatment of osteoporosis and the prevention of skeletal complications in cancer patients. This will provide access and treat patients with bone metastases due to breast, prostate, lung, myeloma, kidney, thyroid, head & neck, and other solid tumours, the Ahmedabad-based drug firm said in a regulatory filing. Metastases, is when the cancer spreads to the bones and other organs in the body indicating an advanced stage of cancer. The company said it has priced 'Zyrifa' at MRP of Rs 12,495. Sharvil P Patel, Managing Director, Zydus Lifesciences Ltd said that with Denosumab 120 mg SC, the company aims to bring access, affordability of medication in cancer patients...

Zydus Wellness Ltd. is trading above its 200 day SMA of 405.7

Zydus Lifesciences shares rise 2% on expanding its biosimilar portfolio

Business Standard | 10 Dec 2025 1 more

Zydus Wellness Ltd.

09 Dec 2025

426.40

0.39%

Company Update

Zydus Wellness Ltd-$ - 531335 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) …

BSE India

Disclosure under SEBI (PIT) Regulations, 2015

pdf

Zydus Wellness Ltd.

02 Dec 2025

426.40

0.39%

Company Update

Zydus Wellness Ltd-$ - 531335 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) …

BSE India

Disclosure under SEBI (PIT) Regulations, 2015

pdf

Zydus Wellness Ltd.

26 Nov 2025

426.40

0.39%

Zydus Lifesciences, RK Pharma sign deal for licensing, commercialisation

Business Standard

Zydus Lifesciences Ltd on Wednesday said it has entered into an exclusive licensing and commercialisation agreement with RK Pharma Inc of the US for a new sterile injectable oncology supportive care product for the US market. Under the terms of this agreement, RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA (new drug application) submission and commercialisation of the product in the US, the company said in a regulatory filing. The product is expected to be filed in 2026 and will provide a formulation that is intended to provide reduced dosing error and enhanced compliance of healthcare professionals, it added. "This partnership reinforces our commitment to delivering high-quality, affordable medicines and improving patient care," Zydus Lifesciences Managing Director Sharvil Patel said. RK Pharma Founder and Executive Chairman Ravishanker Kovi said, "Our collaboration with Zydus, a company with robust regulatory expertise and

Zydus Wellness Ltd. is trading below its 30 day SMA of 442.4

Zydus Lifesciences shares rise after USFDA nod, RK Pharma licensing deal

Business Standard | 26 Nov 2025

Zydus Wellness Ltd.

18 Nov 2025

426.40

0.39%

Zydus partners with SIG to launch single-serve spouted pouches for cough medicine

Business Line

The new format offers precise dosing, better hygiene, and reduced wastage using SIG's advanced filling technology.

Zydus Wellness Ltd. is trading below its 30 day SMA of 442.4

Zydus Wellness Ltd.

13 Nov 2025, 03:47PM

426.40

0.39%

Zydus' Amplitude receives CE mark for its robotic surgical system Andy'

Business Line

This approval means the product complies with European standards for safety, performance, and quality, according to a statement

Zydus Wellness Ltd. has an average target of 550.00 from 5 brokers.

Zydus Wellness Ltd.

11 Nov 2025

426.40

0.39%

Zydus Gets Chinese Health Regulator Nod For Generic Anxiety Drug

NDTV Profit

Venlafaxine ER capsules are indicated for the treatment of major depressive disorder, generalised anxiety disorder, social anxiety disorder and panic disorder.

Zydus Wellness Ltd. has an average target of 550.00 from 5 brokers.

Zydus Lifesciences receives first drug approval in China

Business Line | 11 Nov 2025 1 more

Zydus Wellness Ltd.

07 Nov 2025

426.40

0.39%

Zydus Lifesciences Q2 Review: ICICI Securities Maintains 'Hold', Sees 4% Downside Check New Target Price

NDTV Profit

ICICI Securities raises Zydus Lifesciences FY26/27E earnings by ~2-3% to factor higher sales from recent acqusitions in consumer wellness, medtech divisions.

Zydus Wellness Ltd. has an average target of 550.00 from 5 brokers.

Zydus Life Q2: Solid beat on bottom line, analysts mixed on growth outlook

Business Standard | 07 Nov 2025 3 more

Zydus Wellness Ltd.

06 Nov 2025

426.40

0.39%

Zydus Gets USFDA's Orphan Drug Designation For Beta-Thalassemia Product

NDTV Profit

Beta thalassaemia patients have low levels of haemoglobin, which results in a lack of oxygen in many parts of the body, leading to weakness, fatigue and more serious complications.